title: Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.
abstract: Recent in vitro studies suggest that acyclovir may directly inhibit HIV-1 replication and can select for a specific HIV-1 reverse transcriptase mutation (V75I) with concomitant loss of an anti-HIV-1 effect. We tested for HIV-1 genotypic resistance at reverse transcriptase codon 75 in plasma from 168 HIV-1-infected persons from Botswana, Kenya, Peru, and the United States taking daily acyclovir or valacyclovir for between 8 weeks and 24 months. No V75I cases were detected (95% confidence interval, 0%-2.2%). These prospective in vivo studies suggest that standard-dose acyclovir or valacyclovir does not select for HIV-1 resistance.
authors.affiliation: Department of Global Health, University of Washington, Seattle, Washington, USA.
authors.forename: Jared M
authors.initials: JM
authors.lastname: Baeten
authors.forename: Jairam
authors.initials: J
authors.lastname: Lingappa
authors.forename: Ingrid
authors.initials: I
authors.lastname: Beck
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Frenkel
authors.forename: Gregory
authors.initials: G
authors.lastname: Pepper
authors.forename: Connie
authors.initials: C
authors.lastname: Celum
authors.forename: Anna
authors.initials: A
authors.lastname: Wald
authors.forename: Kenneth H
authors.initials: KH
authors.lastname: Fife
authors.forename: Edwin
authors.initials: E
authors.lastname: Were
authors.forename: Nelly
authors.initials: N
authors.lastname: Mugo
authors.forename: Jorge
authors.initials: J
authors.lastname: Sanchez
authors.forename: Myron
authors.initials: M
authors.lastname: Essex
authors.forename: Joseph
authors.initials: J
authors.lastname: Makhema
authors.forename: James
authors.initials: J
authors.lastname: Kiarie
authors.forename: Carey
authors.initials: C
authors.lastname: Farquhar
authors.forename: Lawrence
authors.initials: L
authors.lastname: Corey
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000494:pharmacology; D000328:Adult; D019943:Amino Acid Substitution / Q000235:genetics; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001902:Botswana; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000821:virology; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D006558:Herpes Genitalis / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D018258:Herpesvirus 2, Human / Q000302:isolation & purification; D006801:Humans; D007630:Kenya; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D020125:Mutation, Missense; D010568:Peru; D017354:Point Mutation; D011446:Prospective Studies; D012641:Selection, Genetic; D017422:Sequence Analysis, DNA; D014481:United States; D000077483:Valacyclovir; D014633:Valine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000998:Antiviral Agents; C514824:reverse transcriptase, Human immunodeficiency virus 1; D054303:HIV Reverse Transcriptase; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir